Washington, DC, and Newtown, CT (PRWEB) July 3, 2008
Strategic Pharmaceutical Advisors (SRxA) and Sinol USA, Inc., announced today the signing of a Memorandum of Understanding signifying their intent to enter into a global marketing agreement for SINOL Nasal Spray. Under the proposed terms of the agreement SRxA will lead the worldwide educational and information support of SINOL Nasal Spray to professional and consumer audiences.
Headquartered in Newtown Connecticut, Sinol USA Inc. is a healthcare company dedicated to the development of products using all natural ingredients. Available without a prescription, SINOL Nasal Spray formulations use clean, old fashioned ingredients for fast relief from allergy and sinus congestion and headaches of all degrees and types.
SRxA is a health education and strategic planning firm with world-renowned physicians as its partners and advisors. As part of this agreement, SRxA will develop programming tailored to the education of professional and consumer audiences and deliver it in a variety of media appropriate for each target audiences. Strategic Pharmaceutical Advisors is headquartered in Washington, DC, with offices in London and Hong Kong.
In announcing this collaboration, Paul Carpenter, Chief Executive Officer of Sinol USA, Inc. noted, "SINOL Nasal Sprays have caught the attention of U.S. medical practitioners in a very short period of time. With this collaboration, we now look forward to expanding our US base and reaching an international physician audience through the proven expertise and global sphere of influence of Strategic Pharmaceutical Advisors."
Dr. Christos S. Efessiou, Strategic Pharmaceutical Advisors' Chief Executive Officer, commented "The option of providing the public with an all natural, non-prescription alternative for relief from allergy-related congestion and headaches, impressed our Team enough to seek an active partnership in SINOL. My colleagues and I are excited at the possibilities that this partnership will offer to healthcare professionals and to allergy and headache sufferers."
Sinol USA is presently working with Strategic BioSciences, a SRxA affiliate, in a pioneering new product reformulation agreement which is expected to offer significant advantages to SINOL users. The two companies expect to announce this agreement in the near future.
Christos S. Efessiou, PhD